Leerink keeps an Outperform rating on MacroGenics (MGNX) with an $8 price target following the Q3 report. The company recently announced it had sold global rights of Margenza to TerSera Therapeutics for $40M upfront and up to $35M in aggregate sales milestones, the analyst tells investors in a research note. The firm views the deal positively, saying it provides non-dilutive financing and will allow MacroGenics to focus on its pipeline efforts.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGNX: